The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer

M.E. ODwyer; B.J. Druker

doi:10.2174/1568009013334250

ISSN: 1568-0096
E-ISSN: 1873-5576

The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
By M.E. ODwyer and B.J. Druker
Source: Current Cancer Drug Targets, Volume 1, Issue 1, May 2001, p. 49 - 57
DOI: https://doi.org/10.2174/1568009013334250
- Available online: 01 May 2001

Abstract

The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.

Article metrics loading...

/content/journals/ccdt/10.2174/1568009013334250

2001-05-01

2025-12-08

From This Site

/content/journals/ccdt/10.2174/1568009013334250

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/content/journals/ccdt/10.2174/1568009013334250

Article Type: Review Article

Keyword(s): allogeneic stem cell; Bcr-Abl associated leukemias; chronic myelomonocytic leukemic; CML blast crisis; myelogenous leukaemia; myelosuppression; optimal anti-leukemic effects; Ph chromosome; Tyrosine Kinase Inhibitor

Most Cited Most Cited RSS feed

- Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
  
  Authors: Yong Lin, Ranxin Shi, Xia Wang and Han-Ming Shen
- The Role of Snail in EMT and Tumorigenesis
  
  Authors: Yifan Wang, Jian Shi, Kequn Chai, Xuhua Ying and Binhua P. Zhou
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
  
  Authors: Amancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, Wolfgang Link and Juan F.M. Leal
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
  
  Authors: D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
  
  Authors: Ziyad Binkhathlan and Afsaneh Lavasanifar
- Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
  
  Authors: M. Abal, J.M. Andreu and I. Barasoain
- Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
  
  Authors: R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson and M.V. Seiden
- The Role of Fibroblast Growth Factors in Tumor Growth
  
  Authors: M. Korc and R. E. Friesel
- Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
  
  Authors: M. Thomson and M. Ali
- Oxidative Stress and Cancer: The Role of Nrf2
  
  Authors: Soraya Sajadimajd and Mozafar Khazaei
More Less

The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer

Abstract

Most Read This Month

Most Cited Most Cited RSS feed